Driving and safety-sensitive work

If you use medicinal cannabis in New Zealand and drive, or work in a safety-sensitive role, the legal line is not whether you have a prescription. It is whether you are impaired. This page gives you a decision rule you can apply before you get behind the wheel or start a shift, and tells you exactly what the law says as of 2024.

---

The one rule that matters

Under New Zealand’s Land Transport Act 1998, it is an offence to drive while impaired by any drug, including medicinal cannabis. A prescription does not create a legal defence. The Ministry of Health’s Medicinal Cannabis Scheme (under the Misuse of Drugs Act) legalises access to prescribed products; it does not create an exemption from road safety law. In 2024, the legal position is clear: if you drive with THC in your system and you are impaired, you can be charged with driving under the influence (DUI). If you drive with a specified amount of THC in your blood, you can be charged with a per se offence, regardless of whether you feel impaired.

The practical question is not “is it legal?” but “how do I manage my prescription, my work, and my driving without breaking the law or endangering anyone?” This page gives you a decision rule you can apply, not a general overview.

The legal frame in New Zealand

Medicinal cannabis products in New Zealand are regulated by the Ministry of Health under the Misuse of Drugs Act 1975 and the Medicinal Cannabis Scheme. Under the scheme, a medical practitioner can prescribe a manufactured cannabis product that meets GMP standards and has been notified to the Ministry of Health. The product is dispensed through a pharmacy, not a dispensary, and the raw plant material is not a legal general licence to use cannabis. This legal framework was confirmed in the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018, effective 1 April 2020.

Land Transport NZ (Waka Kotahi) sets the road rules. Under the Land Transport Act 1998, it is an offence to drive with a blood THC concentration over the legal limit of 2 nanograms per millilitre (ng/mL) of whole blood. This is a per se limit: you do not need to be visibly impaired to be charged. The limit applies to all drivers, including those with a prescription. There is no “medicinal cannabis exemption” for driving in New Zealand. The Ministry of Health’s Medicinal Cannabis Scheme does not override the Land Transport Act 1998. A positive oral fluid test for THC at the roadside is an offence, regardless of prescription status. The only legal way to drive after taking medicinal cannabis is to ensure you are not impaired and to have a valid prescription; even then, police can still prosecute if you are impaired.

The NZ Transport Agency (Waka Kotahi) guidance (2023) states that any amount of THC in oral fluid can lead to a charge if the officer believes you are impaired. The legal blood-THC limit for drivers is 2 ng/mL for those 20 years and over (Land Transport Amendment Act 2022). There is no legal limit for CBD; it is not psychoactive and does not impair driving. However, CBD products may contain trace THC (up to 0.3% in some imported products), so a positive oral fluid test is possible but unlikely at therapeutic doses.

For safety-sensitive workers (e.g., pilots, train operators, heavy vehicle drivers, machinery operators, health workers), the rules are stricter: workplace policies can prohibit any THC even with a valid prescription, and employers are not required to accommodate cannabis use if it poses a safety risk. The NZ Transport Agency (now Waka Kotahi) states that driving under the influence of cannabis is illegal, and there is no legal THC limit for drivers; any amount that impairs is an offence. A prescription does not exempt a driver from impairment laws; the Land Transport Act 1998 and the Land Transport (Offences and Penalties) Regulations 1999 apply.

The clinical decision rule for driving: If you are within 8 hours of last dose of inhaled THC, or 24 hours of oral THC, or if you feel impaired, do not drive. This is a conservative, widely used rule, not a legal test. The police can still charge you under section 58 of the Land Transport Act if they believe you are impaired, regardless of your prescription.

For safety-sensitive work (operating machinery, commercial driving, working at heights, etc.), the rule is stricter: if you take medicinal cannabis, you must disclose it to your employer. Many workplaces treat any detectable THC as a breach, even if you have a prescription. Under New Zealand’s drug testing policies, a positive test does not automatically mean impairment, but it can trigger a workplace process. The Employment Relations Act 2000 requires employers to act fairly, and the Human Rights Act 1993 prohibits discrimination based on disability, which may include a medical condition requiring medicinal cannabis. However, there is no absolute right to use medicinal cannabis in a safety-sensitive role. The decision rests on a risk assessment: the employer must balance the employee’s right to reasonable accommodation against the safety requirements of the role. The reader should not be told that medicinal cannabis is a “right”; it is a clinical and regulatory pathway with conditions.

KEY FACTS: - NZ medicinal cannabis products are governed by the Misuse of Drugs Act and the Medicinal Cannabis Scheme under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019. - Prescribing is limited to medical practitioners registered with the Medical Council of New Zealand; nurse practitioners can also prescribe in certain circumstances. - Medsafe and the Medicinal Cannabis Agency (MCA) administer the scheme. - Products must meet GMP (Good Manufacturing Practice) and be approved by the Ministry of Health. - The patient pathway is: consult a doctor, get a prescription, have it dispensed by a pharmacist, then titrate under medical supervision. - The scheme legalises access via prescription, but the Misuse of Drugs Act still governs the legal framework. - The Medicinal Cannabis Scheme was established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018, which came into force in 2020. - The NZ Formulary lists cannabis products and provides prescribing guidance. - The Medicinal Cannabis Agency (MCA) is part of Medsafe, issues licences, and manages the scheme. - Products must meet GMP standards and be approved by the Ministry of Health. - “Legal medicinal cannabis” does not mean a patient can legally smoke raw plant material or buy unregulated products; the legal product is a manufactured pharmaceutical. - The raw flower, while available, is prescribed and dispensed through a pharmacy, not a dispensary. - Tilray is the most widely prescribed brand in NZ. - Medleaf is an NZ-based importer of Canadian GMP flower and oils. - NUBU Pharmaceuticals is NZ-owned, produces CBD isolate oil and THC oil, the first locally manufactured products. - Aurora, Cann Group, Spectrum Therapeutics, LGP Classic, Helius, MedReleaf, Bedrocan, Cannabisol, Eve are GMP-certified products available in NZ. - THC content is measured in mg/g or %. - CBD content is measured in mg/g or %. - The Medicinal Cannabis Scheme is regulated by the Ministry of Health (Medsafe) under the Misuse of Drugs Act 1975. - Products must be GMP-certified and approved by the Ministry of Health. - Prescribing is restricted to medical practitioners, not nurse practitioners or pharmacists. - The scheme is not a general licence to use cannabis; it is a prescription-based pathway. - Products are dispensed through pharmacies, not dispensaries. - “Legal medicinal cannabis” does not mean smoking raw plant material; the legal product is a manufactured pharmaceutical. - Raw flower is available by prescription but must be dispensed through a pharmacy. - The patient pathway: consult with a medical practitioner, obtain a prescription, present it at a pharmacy, and receive a GMP-certified product. - Common adverse effects: dizziness, dry mouth, drowsiness, increased appetite, gastrointestinal upset, and changes in mood; these are usually dose-related and often settle within a few days. - Severe adverse effects: psychosis, panic attacks, worsening anxiety, paranoia, and (rarely) cannabinoid hyperemesis syndrome; these require immediate medical review. - Interaction warnings: CYP3A4 and CYP2C19 enzyme interactions; cannabis can raise levels of warfarin, clobazam, and some antidepressants; always check the NZ Formulary for interactions. - Driving and safety-sensitive work: THC is impairing; do not drive within 4 hours of inhaling or 8 hours of oral use; do not drive at all in the first week of a new prescription or after a dose change; NZ law sets a zero-tolerance limit for drivers with THC in their blood (3 ng/mL for drivers over 20; under 20 the limit is zero), and the Land Transport Act 1998 makes it an offence to drive with evidence of impairment; there is no “medical exemption” for driving. - Medsafe approval: The product must be a “approved” by Medsafe or the Medicinal Cannabis Agency under the Misuse of Drugs Act; a prescription alone is not enough; the product must be a “controlled drug” approved for supply, and any unapproved product is illegal. - Prescription: A prescription from a medical practitioner under Section 29 of the Misuse of Drugs Act 1975 is the only legal access route. - Medicinal Cannabis Scheme: Established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018, the scheme allows doctors to prescribe, pharmacists to dispense, and the Medicinal Cannabis Agency to license growers and manufacturers. It does not legalise recreational use.